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Cardiac magnetic resonance imaging (CMR) is an
accurate and reliable means of evaluating cardiac
morphology, and therefore very well suited for
identifying and characterizing patients with various
manifestations of left ventricular hypertrophy (LVH)
[1, 2]. For instance, CMR can resolve the question
whether training-induced LVH in athletes is a
physiological rather than a pathophysiological phe-
nomenon [3–5]. A meta-analysis, involving 59 stud-
ies and 1451 athletes (both endurance-trained and
strength-trained athletes), showed that the athlete’s
heart demonstrated normal systolic and diastolic
cardiac function, implying that training-induced
LVH in athletes is predominantly a physiological
phenomenon [6–10]. However, in pathophysiological
LVH, such as in patients with hypertension and
hypertrophic cardiomyopathy, the presence of LVH
portends a poor prognosis whereby there is a negative
relation between prognosis and the stage of LVH
[11–21]. On the other side of the spectrum, a
signiﬁcant decrease in LV mass, such as in patients
following myocardial infarction, may also be
associated with a poor prognosis as these patients
are prone to the development of heart failure [22–39].
Within the latest 10 years, research in LVH as
cardiac target organ damage has uncovered its
prognostic importance. Several studies have indicated
that adequate pharmacological treatment, such as
beta-blocking agents, ACE-inhibition, and angioten-
sin II receptor blockade, is very effective in reducing
LVH [40–47]. In addition, reduction of LV mass is
associated with substantial and signiﬁcant reduction
of cardiovascular morbidity and mortality [46].
Hypertension is strongly associated with increased
risk of subsequent heart failure, and meta-analysis
data have suggested that reduction in blood pressure
and LV mass is associated with very substantial
reductions in incident heart failure [47, 48]. Conse-
quently, LV mass should be accurately calculated as
mass size may have important clinical implications
[49–53].
Generally, LV mass divided by body surface area
(BSA) has been used clinically to account for body
size, but its validity is not fully clear. Methods to
index LV mass for body size have not been inves-
tigated using CMR. In the current issue of the
International Journal of Cardiovascular Imaging,
Brumback et al. [54] sought for new accurate indices
of LV mass. The main purpose of the study was to
develop allometric indices for LV mass measured by
CMR and to compare estimates of the prevalence and
predictive value of LVH deﬁned new allometric
indices. Two indices were derived from linear
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sample of the Multi-Ethnic Study of Atherosclerosis
(MESA) participants. The indices are called allome-
tric as they are proportional to LV mass divided by a
body size variable raised to a scalar exponent. The
authors evaluated 5,004 participants from the MESA
trial with CMR measurements of LV mass without
signs of clinical cardiovascular disease at baseline
who were followed for a median of 4.1 years. The
new indices and limits for hypertrophy (95th percen-
tile) were ﬁnally derived from 822 normal-weight,
normotensive, non-diabetic subjects. There were 107
events consisting of coronary heart disease or stroke.
The estimated prevalence of LVH at baseline and
hazard ratio for events associated with LVH were 8%
and 2.4 with the new allometric height-weight index,
11% and 2.2 with LV mass/BSA, 23–24% and
2.0–2.1 with height indices, and 20% and 1.7 with
un-indexed LV mass. A statistically signiﬁcant dif-
ference was detected between the hazard ratios based
on the new height-weight index and un-indexed LV
mass. It was concluded that the prevalence of
hypertrophy is higher for indices that do not account
for weight. The predictive value of hypertrophy was
signiﬁcantly better with the new allometric height-
weight index than with un-indexed LV mass and may
be better than indices without weight.
The current study is clinically important since an
evaluation of the most suitable indices for LV mass
has not previously been performed using CMR. An
indexed LV mass should be more predictive of a
cardiovascular event than un-indexed LV mass.
Therefore, the authors should be complimented for
developing new allometric indices for CMR-derived
LV mass with potential major implications in clinical
practice.
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